Head-to-head evidence
Albuvirtide vs LP-98
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp41 · full HIV pipeline
Albuvirtide · Aikening
Marketed by Frontier Biotechnologies
NCT02369965 · Phase 3 · completed
The study randomly assigned 418 participants to an active comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2028 · NCT07727642 (registry estimate)
LP-98
Developed by Shanxi Kangbao Biological Product
NCT06560489 · Phase 1/2 · completed
The study randomly assigned 40 participants to four blinded LP-98 dose groups, but it did not include a placebo or active-control arm. Its primary outcomes were laboratory, vital-sign, and electrocardiographic measures rather than hard clinical outcomes, and the primary results are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuvirtide's landscape · LP-98's landscape